We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 1,405,000 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/12/2022 09:33 | They certainly have a great incentive to keep doing deals that will send the share price rocketing over the next few years and it is one of those stocks that could attract a big in fact hug4e buyout for all it's patents imo. The deal already signed is worth a lot more than 7p a share, so the sky is the limit if your happy to hold long term DYOR | clocktower | |
15/12/2022 09:26 | Yes I misread the top part - other employees got options too. I thought the CBO would be in the 'PDMR' table, but obviously not. | on target | |
15/12/2022 09:23 | in reply to someone I am pretty sure that CBO will have some of these new options. & hence that that poster was incorrect. | smithie6 | |
15/12/2022 09:17 | We seemed to be forming a base of around 6p I thought, so may soon get back there imo. | clocktower | |
15/12/2022 09:17 | We seemed to be forming a base of around 6p I thought, so may soon get back there imo. | clocktower | |
15/12/2022 09:17 | We seemed to be forming a base of around 6p I thought, so may soon get back there imo. | clocktower | |
15/12/2022 08:54 | Much better and I am running with the bulls and have added again this morning. | clocktower | |
15/12/2022 08:54 | Much better and I am running with the bulls and have added again this morning. | clocktower | |
15/12/2022 08:54 | Cannot buy 50k online now | clocktower | |
15/12/2022 08:51 | Looking better today. | manual dexterity | |
15/12/2022 08:49 | Battle of bulls and bears as expected today. Will we now see director buying? | clocktower | |
14/12/2022 21:31 | They do not have to pay anything for these options but have to meet the terms set out in the RNS bocker01 | clocktower | |
14/12/2022 21:12 | That’s what I couldn’t understand Love wins. What do they have to pay to exercise these free options. The strike price. Where is it disclosed? | bocker01 | |
14/12/2022 20:54 | What is the performance criteria? The strike price? I prefer it when this is clearly detailed - eg at 20p. Ideally on a scale, such as 15p/20p/25p tranches. I think there needs to be plenty more in the near term pipeline to justify this award. Agree about the CBO though, On Target. It does not change the investment case, but I do not see the market viewing this as excellent news. The CEO and CFO are salaried, not working on a share-only agreement. I do not see this as acting as a positive catalyst for the share price tomorrow, but would be happy to be wrong. Not long to find out anyway. | lovewinshatelosses | |
14/12/2022 20:23 | ref. CBO you phps need a hand to interprete the RNS ;-) (apologies for my appearring a bit arrogant) (The RNS does "not" say that CBO has not received any options, as you have written) | smithie6 | |
14/12/2022 19:45 | Should rise tomorrow on this excellent news. The directors have been incentivised to run the company well for at least the next 3 years. The options might be 'free' financially but they have to stay at the company for at least 3 years for them to get anything at all, and the company progress and shareprice have to meet performance criteria. Directors (at least the ones who got options) are therefore fully aligned with shareholders interests. This is good news, for those who understand how incentive options work. My only complaint is that the CBO didn't get any of these given she apparently played a key role in obtaining the recent $160m licencing deal, unless she hasn't been at the company long enough? | on target | |
14/12/2022 19:42 | I am happy that at the current share price the CFO’s options only amount to a decent littlebonus and bearing in mind that they vest in three years time and they have the terms clearly set out, I do not think it unreasonable. As for Dr Jones total of 10 million plus you must look at the deals they have already pulled off. It is not as though the options were given before the deal. We know the current share price undervalues the company based on that last deal alone, so a fair reward in total of £500k at the current level is not unreasonable imo. Let’s hope the share price is £1 when he can sell them. Good luck to him and all employees that are benefiting from this award. | clocktower | |
14/12/2022 18:53 | This has now become a trading share, buy under 4.5p and sell over 5.5p.Will expect the shares down tomorrow. | kickingking | |
14/12/2022 18:48 | If the nan in the Catherine Tate show was here she would saying "F@@king liberties "I did state two interviews back, that they looked more upset about not being given free options. Why would they buy in the open market when between these two, they will own over 4% of the company without having to spend a penny of their own cash. Look at their holdings, just over 100k shares between both, that they have actually bought. It's pathetic. Why should PI trust these two.I stated when I last sold that I would look to buy back in when they buy in the open market. I doubt that they will buy any substantial amount. Let's see what excuse they will use at the next meeting. You could see that finance director squirming in his seat having to take that question. | kickingking | |
14/12/2022 18:11 | I couldn’t quite see what they have to pay to exercise these options? Anyone able to enlighten me? Must be obvious and I make apologise for appearing to be a half-wit! | bocker01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions